Healing effects of agomelatine on methotrexate-induced Kidney damage in rats
Author(s): Nurhan Gumral, Ozlem Ozmen, Rahime Aslankoc, Arzu Yalcin* and Oguzhan Kavrik
Abstract
MTX is a chemotherapeutic agent widely used in the treatment of some types of cancer (as in acute lymphoblastic leukemia and lymphoma) as well as inflammatory disorders as rheumatoid arthritis. Agomelatonin is a molecule synthesized and released in the pineal gland as a synthetic anologue of the hormone melatonin. Agomelatonin has a strong agonist effect on the melatonin hormone receptors MT1 and MT2. Twenty-four 3-4 months old male Wistar albino rats were randomly divided into three groups of eight rats. MTX group was administered a single dose of 20 mg/kg MTX i.p. on the second day of the experiment. Ago group a single dose of 40 mg/kg AGO was given by oral gavage for 7 days. AGO group, BUN and creatine levels decreased statistically significantly compared to the MTX group. There was a statistically significant increase in TAS levels in the AGO group compared to the MTX group (p=0.001). There was a statistically significant decrease in the TOS levels of the AGO group compared to the MTX group (p=0.046). Immunohistochemically increase in iNOS, HSP-70, OPN and CGSF immunoreactions in both epithelial and mesenchymal cells of the kidneys were observed in the MTX group. Treatment of rats with AGO significantly reduced MTX-induced renal toxicity. Finally, the results suggest that AGO has a protective effect against MTX-induced oxidative stress renal toxicity.